Intercept to Present at Upcoming Investor Conference
- 37th Annual
J.P. Morgan Healthcare Conferenceat 2:30 p.m. PTon Wednesday, January 9, 2019.
Webcast information for this event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An archived webcast will be available on Intercept’s website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in
For more information about Intercept, please contact:
Media inquiries: firstname.lastname@example.org
Source: Intercept Pharmaceuticals, Inc.